AT Bancorp cut its position in Medtronic PLC (NYSE:MDT) by 87.1% during the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 8,899 shares of the medical technology company’s stock after selling 60,196 shares during the period. AT Bancorp’s holdings in Medtronic PLC were worth $684,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Capstone Asset Management Company boosted its position in shares of Medtronic PLC by 37.1% in the fourth quarter. Capstone Asset Management Company now owns 346,388 shares of the medical technology company’s stock worth $26,644,000 after buying an additional 93,753 shares in the last quarter. Beese Fulmer Investment Management Inc. boosted its position in shares of Medtronic PLC by 2.2% in the fourth quarter. Beese Fulmer Investment Management Inc. now owns 55,486 shares of the medical technology company’s stock worth $4,268,000 after buying an additional 1,193 shares in the last quarter. Vontobel Asset Management boosted its position in shares of Medtronic PLC by 4.1% in the fourth quarter. Vontobel Asset Management now owns 1,915,494 shares of the medical technology company’s stock worth $154,575,000 after buying an additional 74,733 shares in the last quarter. Bank of The West boosted its position in shares of Medtronic PLC by 5.7% in the fourth quarter. Bank of The West now owns 11,696 shares of the medical technology company’s stock worth $900,000 after buying an additional 628 shares in the last quarter. Finally, Cullinan Associates boosted its position in shares of Medtronic PLC by 20.3% in the fourth quarter. Cullinan Associates now owns 116,337 shares of the medical technology company’s stock worth $8,949,000 after buying an additional 19,636 shares in the last quarter.

Medtronic PLC (NYSE:MDT) opened at 76.09 on Tuesday. The stock has a market cap of $106.99 billion and a PE ratio of 43.48. The company’s 50-day moving average is $75.98 and its 200 day moving average is $74.56. Medtronic PLC has a 52 week low of $55.54 and a 52 week high of $79.50.

Medtronic PLC (NYSE:MDT) last announced its quarterly earnings data on Thursday, December 3rd. The medical technology company reported $1.03 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.00 by $0.03. The firm had revenue of $7.10 million for the quarter. During the same quarter last year, the business earned $0.96 earnings per share. The business’s revenue was up 61.7% compared to the same quarter last year. On average, analysts expect that Medtronic PLC will post $4.38 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, January 15th. Investors of record on Thursday, December 24th were given a dividend of $0.38 per share. This is a boost from Medtronic PLC’s previous quarterly dividend of $0.26. This represents a $1.52 annualized dividend and a yield of 1.98%. The ex-dividend date of this dividend was Tuesday, December 22nd.

A number of research analysts have recently issued reports on MDT shares. Deutsche Bank reiterated a “buy” rating on shares of Medtronic PLC in a report on Thursday, October 15th. BTIG Research reissued a “buy” rating and set a $84.00 price target on shares of Medtronic PLC in a research report on Wednesday, October 21st. Zacks Investment Research raised shares of Medtronic PLC from a “hold” rating to a “buy” rating and set a $84.00 price target on the stock in a research report on Saturday, January 16th. Evercore ISI raised shares of Medtronic PLC from a “hold” rating to a “buy” rating and raised their price target for the company from $70.94 to $80.00 in a research report on Thursday, October 8th. Finally, JPMorgan Chase & Co. raised their price target on shares of Medtronic PLC from $82.00 to $88.00 and gave the company an “overweight” rating in a research report on Monday, November 16th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $86.13.

In related news, EVP Bryan C. Hanson sold 5,000 shares of the stock in a transaction dated Friday, January 8th. The shares were sold at an average price of $75.00, for a total transaction of $375,000.00. Following the sale, the executive vice president now directly owns 106,514 shares of the company’s stock, valued at approximately $7,988,550. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Richard Kuntz sold 13,715 shares of the stock in a transaction dated Friday, December 4th. The shares were sold at an average price of $78.06, for a total transaction of $1,070,592.90. Following the sale, the vice president now directly owns 108,086 shares in the company, valued at $8,437,193.16. The disclosure for this sale can be found here.

Medtronic plc (NYSE:MDT) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes Cardiac Rhythm & Heart Failure, Coronary & Structural Heart and Aortic & Peripheral Vascula. Its Minimally Invasive Technologies Group segment includes Surgical Solutions and Patient Monitoring and Recovery. Its Restorative Therapies Group segment includes Spine, Neuromodulation, Surgical Technologies and Neurovascular. Its Diabetes Group segment includes Intensive Insulin Management, Non-Intensive Diabetes Therapies and Diabetes Services & Solutions. Medtronic, Inc. is a subsidiary of the Company.

12 Month Chart for NYSE:MDT

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Medtronic PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic PLC and related companies with MarketBeat.com's FREE daily email newsletter.